At the Oncology Nursing Society 2018 Congress, Susan D. Scott, PhD, RN, addresses the secondary trauma endured by clinicians when a patient dies because of an unexpected medical event, and the peer-to-peer support team that she and her colleagues formed at her clinic.
At the 2018 Cancer Survivorship Symposium, Margaret Rosenzweig, PhD, CRNP-C, AOCN, FAAN, explains how initial training in survivorship care is lacking for nurse practitioners, and how she and her colleagues developed a web-based training program to address this issue.
At the 2018 Cancer Survivorship Symposium, Cathy J. Bradley, PhD, MPA, discusses the topic of cancer survivors returning to the workforce, and the multitude of barriers these individuals face when returning to work.
According to data presented at the 2018 Multidisciplinary Head and Neck Cancers Symposium, a shorter interval from surgery to the start of radiation therapy has been linked to improved survival in patients with head and neck cancers.
Non-Hodgkin lymphoma (NHL) is far less predictable than Hodgkin lymphoma, and is more likely to spread to parts of the body outside of the lymphatic system.
Cristi Radford, MS, CGC, and Michele Gabree, MS, CGC, explain what variants of uncertain significance are, and address some of the questions that are frequently asked by providers.
The FDA granted accelerated approval to nivolumab based on a notable clinical benefit in a subset of patients who progressed after receiving the standard first-line chemotherapy with fluoropyrimidine, oxaliplatin, and irinotecan.
“Compared to those not enrolled in clinical trials, the evidence shows that the minority patients participating in clinical trials had increased overall survival,” said Khilen B. Patel, MD, at the 2018 Society of Gynecologic Oncology Annual Meeting on Women’s Cancer.
To sign up for our newsletter or print publications, please enter your contact information below.
